Roivant Sciences Ltd. (ROIV) recently received approval for LISRAYA, providing a solid commercial foundation for the company. Additionally, their drug brepocitinib has potential to expand into a broader immunology franchise. ROIV's pulmonary drug candidate mosliciguat shows promise for improving vascular resistance and walking distance, potentially becoming a valuable franchise pending Phase 3 trial results. Overall, ROIV's valuation appears attractive if management meets long-term sales targets.
Social Security benefits are projected to drop by 22% by 2032, forcing average Americans to increase their retirement savings by over 30%. To address this, a diversified portfolio focusing on income through high-quality dividend-paying stocks like An...
Bitcoin ETFs experienced a fourth consecutive day of outflows, losing $13.29 million on September 11 and $462.73 million over the week, with BlackRock's IBIT seeing significant withdrawals. In contrast, Ethereum ETFs attracted $216.41 million in infl...
Grayscale has filed to convert its Litecoin Trust (LTCN) into an ETF, proposing a name change to Grayscale Litecoin Trust ETF while retaining the LTCN ticker. This move aims to list LTCN on the NYSE Arca exchange, allowing share creation and redempti...
Ethereum has recovered more than 55% from its June low of around $1,600 to trade near $2,492, marking one of its strongest third quarters in history. The rally gained momentum in August, pushing ETH above key moving averages and breaking through resi...
Bitcoin fell below $77,000 to around $76,725 during Sunday trading, pressured by rising treasury yields and expectations of sustained high interest rates. Market sentiment briefly hit an "extreme greed" level not seen since March 2024, reflecting str...
